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Introduction
Left ventricular hypertrophy is a maladaptive response to 
cardiac insults such as hypertension, damage, or aging (Dorn, 
2007), and predisposes to heart failure and sudden death (Haider 
et al., 1998). Initially, the heart is enlarged through hypertrophy 
of individual cardiomyocytes and extensive fibrosis within the 
ventricular wall. As the condition evolves, myocyte death is 
common and promotes the progression to heart failure. Studies 
in both animals and humans have indicated that remediation of 
the hypertrophic phenotype at the early stages of the disease 
improves outcome without compromising cardiac function 
(Hill et al., 2000; Kjeldsen et al., 2002). Hence, gaining a greater 
understanding of the mechanisms responsible for left ventricular 
hypertrophy may suggest novel therapeutic strategies.
Structural and molecular remodeling instigates pathologi-
cal growth of the heart. Many of these maladaptive changes 
develop as a result of altered cardiomyocyte transcriptional 
Inositol 1,4,5-triphosphate receptor II (IP3RII) calcium channel expression is increased in both hypertrophic failing human myocardium and experimentally in-
duced models of the disease. The ectopic calcium released 
from these receptors induces pro-hypertrophic gene ex-
pression and may promote arrhythmias. Here, we show 
that IP3RII expression was constitutively restrained by the 
muscle-specific miRNA, miR-133a. During the hypertro-
phic response to pressure overload or neurohormonal 
stimuli, miR-133a down-regulation permitted IP3RII levels to 
increase, instigating pro-hypertrophic calcium signaling 
and concomitant pathological remodeling. Using a com-
bination of in vivo and in vitro approaches, we demon-
strated that IP3-induced calcium release (IICR) initiated 
the hypertrophy-associated decrease in miR-133a. In this 
manner, hypertrophic stimuli that engage IICR set a feed-
forward mechanism in motion whereby IICR decreased 
miR-133a expression, further augmenting IP3RII levels and 
therefore pro-hypertrophic calcium release. Consequently, 
IICR can be considered as both an initiating event and 
a driving force for pathological remodeling.
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and miR-208a (van Rooij et al., 2007) show altered expression 
in hypertrophy and have been directly implicated in induction 
of the hypertrophic response. These disease-associated profiles 
of miRNA expression are likely to be generated in response to 
hypertrophic stimuli by modification of miRNA transcription or 
processing mechanisms, elicited by the activity of intracellular 
signaling pathways. Defining precisely how miRNA expression 
and pro-hypertrophic pathways are interrelated is likely to pro-
vide important insight into the complexity of cardiomyocyte 
gene regulatory networks.
Here, we investigate the mechanisms that produce up- 
regulation of IP3RII during hypertrophic cardiomyocyte remod-
eling, showing that decreased expression of miR-133a allows 
IP3RII expression to increase, thereby promoting hypertrophy. 
Furthermore, by identifying that calcium released from IP3RII 
suppresses miR-133a levels, we delineate a pro-hypertrophic 
positive feedback loop initiated and perpetuated by IICR.
Results
IP3RII protein expression increases in the 
cardiomyocyte during pressure overload–
induced hypertrophy
To examine the mechanisms responsible for increased IP3- 
dependent signaling during pathological cardiac remodeling, 
we used an in vivo hypertrophy model. Aortic banding (AB) in-
duces a pressure-overload hypertrophic response and eventual 
heart failure in adult rats, exemplified by an increase in the ratio 
of left ventricular weight to body weight (Fig. 1 a) and enhanced 
mRNA expression of the hypertrophic marker gene atrial natri-
uretic factor (ANF; Fig. 1 b). Echocardiography confirmed the 
presence of pathological left ventricular remodeling and contrac-
tile dysfunction (Fig. 1, c and d). Our previous observations have 
demonstrated an increase in IP3RII protein expression that is re-
stricted to the cardiomyocytes of the hypertrophic heart (Harzheim 
et al., 2009, 2010). This response is not recapitulated in the non-
cardiomyocyte population, which expresses negligible amounts 
of IP3RII protein under both control (Perez et al., 1997; Harzheim 
et al., 2010) and hypertrophic conditions (Harzheim et al., 2009, 
2010). Consistent with these data, immunoblotting demonstrated 
that IP3RII protein expression was increased in the AB samples 
(Fig. 1, e and f). Up-regulation of IP3RII within the cardiomyo-
cyte specifically was shown in immunofluorescence images of 
ventricular myocytes isolated from sham and AB rats (Fig. 1 g). 
Quantitation of the intensity and distribution of immunostained 
proteins by 2D Fourier analysis showed that expression of IP3RII 
was increased in the AB samples, whereas RyR2 expression and 
distribution were unaltered (Fig. S1, a and b). Furthermore, the 
ratio of pixels positive for IP3RII to RyR2 was increased in the 
hypertrophic myocytes (Fig. 1 h). Together, these data confirm 
that the increase in IP3RII protein during hypertrophy is myocyte 
specific. Intriguingly, abundance of IP3RII mRNA was unaltered 
(Fig. 1 i) and nascent IP3RII RNA expression, a measure of 
transcriptional activity at the IP3RII gene (Itpr2) locus, was 
decreased after AB (Fig. 1 j). Consequently, we considered 
a post-transcriptional regulatory mechanism to explain pro-
hypertrophic IP3RII up-regulation in the cardiomyocyte.
profiles, induced through the coordinated action of a network 
of transcription factors activated by neurohormonal stimuli and/
or stretch (Wu et al., 2006; Higazi et al., 2009). This produces 
genome-wide changes in gene expression and permits expres-
sion of the proteins responsible for pathological myocardial 
growth. Signaling pathways regulated by changes in intracellu-
lar calcium are central to the transduction of pro-hypertrophic 
stimuli, governing the activation of transcriptional regulatory 
mechanisms including calcineurin-nuclear factor of activated 
T cells (Cn-NFAT; Higazi et al., 2009; Nakayama et al., 2010; 
Rinne and Blatter, 2010) and CaM-dependent kinase II–histone 
deacetylase 4–myocyte enhancer factor 2 (CaMKII–HDAC4–
MEF2; Wu et al., 2006). During hypertrophy and heart failure, 
activity of these regulators is enhanced as a consequence of the 
increased amplitude and altered localization of their upstream 
stimulatory calcium signals. For example, adult ventricular my-
ocytes express low levels of the inositol 1,4,5-triphosphate II 
(IP3RII) calcium channel within the membranes of the sarco-
plasmic and perinuclear calcium stores at baseline (Lipp et al., 
2000; Guatimosim et al., 2008; Luo et al., 2008; Higazi et al., 
2009). However, in failing human myocardium and cardiomyo-
cytes from genetic and experimentally induced animal models 
of hypertrophy, IP3RII levels are increased (Harzheim et al., 
2009, 2010; Nakayama et al., 2010). Under these conditions, 
IP3-induced calcium release (IICR) from IP3RII has deleterious 
effects on cellular function. Ectopic release of calcium from the 
sarcoplasmic reticulum has pro-arrhythmic properties (Harzheim 
et al., 2009), while IICR in the perinuclear region engages the 
activity of calcium-dependent transcriptional regulators, leading 
to the induction of pro-hypertrophic patterns of gene expression 
(Wu et al., 2006; Higazi et al., 2009; Guo et al., 2012). Intrigu-
ingly, we have previously reported that increased protein ex-
pression of IP3RII during hypertrophy is not accompanied by an 
increase at the mRNA level (Harzheim et al., 2009), suggesting 
that receptor expression is up-regulated post-transcriptionally.
Notably, post-transcriptional regulatory mechanisms are 
known to fulfill a critical role in both cardiac development and 
disease (Small and Olson, 2011) and commonly involve the 
activity of micro-RNAs (miRNAs). miRNAs are small noncoding 
RNAs that influence gene expression by binding to sequences 
that include the 3 untranslated region (3UTR) of newly syn-
thesized mRNA transcripts. As a result, protein expression from 
these transcripts is inhibited by mRNA degradation or transla-
tional repression (Bartel, 2004). The power of miRNA-mediated 
regulation of gene expression is illustrated by the observation 
that a single miRNA can target hundreds of mRNAs (Lim et al., 
2005; Matkovich et al., 2011), providing a mechanism whereby 
a network of genes can be subject to coordinated and simultane-
ous regulation. Consequently, a change in the pattern of miRNAs 
expressed by a cardiomyocyte could generate genome-wide 
remodeling of gene expression and hence induce hypertrophy. 
Consistent with this hypothesis, miRNA expression is altered in a 
diagnostic manner in left ventricular samples taken from humans 
suffering from a variety of cardiac pathologies (Ikeda et al., 
2007) and in mouse models of hypertrophic remodeling (van 
Rooij et al., 2006). More specifically, miRNAs including miR-1 
(Sayed et al., 2007; Li et al., 2010b), miR-133a (Carè et al., 2007), 
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This result is in concordance with the observation that IP3RII pro-
tein expression is unaltered in noncardiomyocytes under hypertro-
phic conditions (Harzheim et al., 2010), suggesting that miR-133a 
and IP3RII expression levels may be inversely correlated. The ge-
nomic sequence encoding miR-133a is clustered bi-cistronically 
with the sequence for another muscle-specific miRNA, miR-1. 
Quantification of miR-1 levels in the AB samples demonstrated 
that expression of this miRNA is also decreased in hypertrophy 
(Fig. 2 c). However, as the Itpr2 3UTR does not contain a seed se-
quence for miR-1, we chose to focus on regulation of IP3RII ex-
pression by miR-133a in our subsequent experiments.
Hence, to verify that IP3RII mRNA is a bona fide target 
for miR-133a, we analyzed the activity of a luciferase reporter 
that tests for miRNA regulation of potential target sequences. In 
this reporter, the 3UTR of the Itpr2 was inserted downstream 
of constitutively expressed luciferase (Fig. 2 d). As a control, 
the putative miR-133a seed sequence within the Itpr2 3UTR 
IP3RII expression is regulated by miR-133a
miRNAs are powerful mediators of post-transcriptional control of 
gene expression networks and have proven roles in cardiac devel-
opment and disease (Small and Olson, 2011). To determine whether 
IP3RII expression is regulated in this manner, we visually inspected 
the 3UTR of the Itpr2 gene for putative seed sequences for hyper-
trophy-related miRNAs. This analysis revealed a seed sequence for 
the anti-hypertrophic miRNA rno-miR-133a (Carè et al., 2007), 
which was conserved between rat, mouse, and human (Fig. 2 a). In 
view of this finding and previously published data that have dem-
onstrated repression of miR-133a in hypertrophy (Carè et al., 
2007), we measured miR-133a expression after AB. miR-133a lev-
els were decreased in the AB samples (Fig. 2 b), thereby providing 
a potential mechanism for the increase in IP3RII expression. The 
hypertrophy-associated decrease in miR-133a expression was 
specific to the cardiomyocyte population, as after AB, miR-133a 
expression in noncardiomyocytes was unchanged (Fig. S1 c). 
Figure 1. IP3RII is up-regulated post-tran-
scriptionally during hypertrophy in cardiac 
myocytes. (a) Quantification of the ratio of 
left ventricular weight to body weight in sham 
and AB adult rats. (b) Analysis of ANF mRNA 
expression by qPCR in sham and AB left ven-
tricular samples. (c) Representative echocar-
diography of sham and AB rats. Dimensions 
indicate left ventricular diastolic dimension 
(LVDd) and posterior wall thickness (PWd), in-
dices of ventricular function and hypertrophy, 
respectively. (d) Fractional shortening quantifi-
cation (%) from echocardiographic analysis of 
eight sham and six AB rats. (e) Immunoblot for 
IP3RII in the membrane protein fraction of sham 
and AB ventricular lysates. Calnexin (CLNX) 
and calsequestrin (CSQ) are shown as loading 
controls. (f) Quantification of immunoblots as 
in e; n = 5. (g) Immunofluorescence image of 
ventricular myocytes isolated from sham and 
AB rats. IP3RII is shown in red, RyR2 in green, 
and DAPI in blue. Bar, 5.8 µm. (h) Ratio of 
IP3RII to RyR2 quantified from immunofluores-
cence images as in g. For the sham condition, 
16 cells from 2 independent preparations were 
analyzed. For the AB condition, 26 cells from 
2 independent preparations were analyzed. 
(i) IP3RII mRNA expression measured by qPCR 
in sham/AB samples. (j) Nascent IP3RII RNA 
expression measured by qPCR in the sham/AB 
samples. Bar graphs are mean ± SEM from 
at least three independent experiments. *, P < 
0.05; ***, P < 0.001.
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miR-133a overexpression decreases IP3RII 
protein levels
To dissect the mechanisms underlying miR-133a regulation of 
the IP3RII, we conducted experiments using primary cultures of 
neonatal rat ventricular myocytes (NRVMs). First, we increased 
miR-133a expression using an adenoviral approach. miR-133a 
overexpression was confirmed by quantitative real-time PCR 
(qPCR; Fig. 3 a) and viral infection was monitored by the pres-
ence of coexpressed GFP (Fig. 3 b). In concordance with our 
hypothesis, miR-133a–overexpressing myocytes exhibited de-
creased IP3RII expression when compared with control myo-
cytes (Fig. 3, c and d). These data indicate that increasing 
miR-133a down-regulates IP3RII.
Inhibition of miR-133a elicits IICR-
dependent hypertrophic remodeling
To further establish the effect of miR-133a upon IP3RII expres-
sion, we inhibited miR-133a binding to its targets by antagomir 
transfection. In the presence of the antagomir, basal levels of the 
IP3RII were increased and the repressive effect of miR-133a 
overexpression was prevented (Fig. 3 e). This result indicates 
that under nonstimulated conditions in NRVMs, miR-133a 
was mutated to prevent miR-133a association. Co-transfection 
of the luciferase reporters and a miR-133a expression plas-
mid into HEK293 cells revealed that luciferase activity was 
decreased by the wild-type Itpr2 3UTR but not the mutant 
Itpr2 3UTR (Fig. 2 e). Therefore, the Itpr2 3UTR contains a 
functional miR-133a binding site. To substantiate these results, 
we analyzed IP3RII protein and mRNA expression in ven-
tricular samples from miR133a-1, miR133a-2 double-knockout 
mice (Fig. 2, f–h; Liu et al., 2008). In the absence of miR-133a, 
IP3RII protein levels were increased (Fig. 2, f and g) while 
IP3RII mRNA expression was diminished (Fig. 2 h). Together, 
these data confirm that miR-133a regulates IP3RII post- 
transcriptionally. Although the 3UTRs of Itpr1and Itpr3 do 
not contain seed sequences for miR-133a, the abundance of 
their protein products was also examined. Expression of IP3RI 
and IP3RIII were unaltered in the hearts of knockout animals 
(Fig. 2 g), confirming that these receptor isoforms are not a 
target for miR-133a and that up-regulation of IP3 receptors is 
not a general consequence of the miR-133a knockout pheno-
type. Together, these results imply that lack of miR-133a– 
mediated repression during hypertrophy augments IP3RII 
protein expression.
Figure 2. miR-133a regulates IP3RII expression. (a) Conservation of the miR-133a seed sequence between the human, mouse, and rat Itpr2 3UTR. (b) miR-133a 
expression in sham and AB samples measured by qPCR. (c) miR-1 expression in sham and AB samples. (d) Schematic representation of the luciferase 
reporter construct used to measure miR-133a repressive activity at the Itpr2 3UTR. (e) Luciferase activity in HEK293 cells transfected with miR-133a and 
either the Itpr2 3UTR reporter or mut-Itpr2 3UTR reporter. (f) Immunoblot for IP3RII in left ventricular samples from wild-type (WT) or miR-133a-1, miR-133a-2 
double knockout mice (dKO). (g) Quantification of immunoblots for IP3RI/II/III from WT/dKO samples as in f; n = 6. (h) IP3RI/II/III mRNA expression in 
samples as in f. Bar graphs represent the mean ± SEM from at least three independent experiments. *, P < 0.05; **, P < 0.01.
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ANF mRNA expression and cell surface area were increased in 
NRVMs transfected with the miR-133a antagomir (Fig. 3, h and i). 
Notably, in the presence of GFP-5P, antagomir transfection did 
not elicit an increase ANF mRNA expression (Fig. 3 h) or cell 
surface area (Fig. 3 i), indicating that IICR is required for the 
pro-hypertrophic effect of antagomir transfection. More signifi-
cantly, these results suggest that when miR-133a activity is de-
creased, as is observed during hypertrophy in vivo (Fig. 1), 
IP3RII expression increases and can initiate IICR-dependent 
cellular remodeling.
Basal IP3RII expression is restricted  
by miR-133a
As miRNAs can target multiple different mRNAs (Bartel and 
Chen, 2004), a direct link between miR-133a, IP3RII, and hy-
pertrophy was lacking. To establish such a link, we transfected 
restrains IP3RII expression. Because IICR from IP3RII is an 
important inducer of hypertrophic remodeling (Higazi et al., 
2009; Nakayama et al., 2010), we next hypothesized that the 
increased IP3RII expression resulting from antagomir transfec-
tion contributes to the pro-hypertrophic effect of miR-133a 
inhibition. To test this hypothesis, we investigated whether sup-
pression of IICR in NRVMs prevents the hypertrophic remodel-
ing induced by miR-133a antagomir (Fig. 3 f). Confirming the 
dependence of the hypertrophic response on IICR and as we 
have previously described, adenoviral overexpression of GFP-
tagged type 1 IP3 5-phosphatase (GFP-5P) suppressed the induc-
tion of ANF mRNA expression elicited by the pro-hypertrophic 
agonist endothelin-1 (ET-1; Fig. 3 g; Higazi et al., 2009; Drawnel 
et al., 2012). We next examined the effect of GFP-5P inhibition 
of IICR upon miR-133a antagomir-induced hypertrophic remod-
eling. Consistent with the anti-hypertrophic role of miR-133a, 
Figure 3. miR-133a inhibits IP3RII expression restraining pro-hypertrophic IICR. (a) Overexpression of miR-133a-GFP in neonatal rat ventricular myocytes 
(NRVMs) quantified by qPCR. (b) Immunofluorescence image of NRVMs expressing GFP/GFP-miR-133a. GFP is shown in green, -actinin in red, and DAPI 
in blue. (c) Immunoblot for IP3RII in GFP/GFP-miR-133a overexpressing NRVMs. (d) Quantification of immunoblots from samples as in c; n = 8. (e) IP3RII 
expression measured by immunoblotting (n = 6) in NRVMs transfected with a control oligo or miR-133a–specific antagomir and infected with GFP/GFP-
miR-133a. (f) Immunofluorescence image of NRVMs expressing GFP/GFP-5P. GFP is shown in green, -actinin in red, and DAPI in blue. (g) ANF mRNA 
expression in NRVMs expressing GFP/GFP-5P and treated with 100 nM endothelin-1 (ET-1) for 24 h. (h) ANF mRNA expression in NRVMs transfected with 
control/miR-133a–specific antagomir and infected with GFP/GFP-5P. (i) Cell surface area quantification in NRVMs transfected and infected as in h. Data 
are mean ± SEM from at least three independent experiments.*, P < 0.05; ***, P < 0.001.
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rat (SHR) model of cardiac hypertrophy. These animals have 
a disease progression that closely mirrors that observed in 
human patients (Dillmann, 2008), as they develop hypertension, 
cardiac hypertrophy, and heart failure with increasing age. As 
observed in hearts from AB rats, isolated hypertrophic adult 
SHR myocytes exhibited an increase in IP3RII protein expres-
sion, unaltered IP3RII RNA levels (Fig. 4 e), and decreased 
expression of miR-133a (Fig. 4 f) when compared with the 
Wistar Kyoto (WKY) control. Befitting their hypertrophic status, 
ANF expression was increased in SHR myocytes (Fig. 4 g). 
Upon miR-133a overexpression, ANF expression returned 
to the control level (Fig. 4 g), indicating regression of the hyper-
trophic phenotype.
To establish a link between miR-133a–mediated regu-
lation of IP3RII and hypertrophic remodeling in vivo, we ana-
lyzed mice infused via an osmotic mini-pump for 1 mo with 
saline or a miR-133a–specific antagomir oligo (Carè et al., 
2007). It has been previously reported that inhibition of the 
activity of miR-133a by antagomir infusion elicits a hypertro-
phic response (Carè et al., 2007). This was exemplified by 
increased diastolic left ventricular posterior wall dimension 
(LVPWd) in the antagomir-treated mice (Fig. 4 h). Therefore, in 
the absence of miR-133a, hypertrophy is induced. Consistent 
with its role in hypertrophic remodeling, IP3RII protein expres-
sion was enhanced under antagomir-treated conditions (Fig. 4, 
i and j). Comparison of IP3RII protein levels in control mice and 
mice infused with a scrambled miR-133a antagomir revealed 
that IP3RII expression was unaffected by the scrambled oligo-
nucleotide (Fig. S4, a and b). Hence, up-regulation of IP3RII is 
a specific effect of the miR-133a antagomir. Taken with the data 
arising from miR-133a inhibition/overexpression in neonatal 
and adult cardiomyocytes in vitro (Fig. 4, b, c, and g), these re-
sults demonstrate that miR-133a inhibits IP3RII expression in 
ventricular myocytes, restraining pro-hypertrophic IICR and 
preventing hypertrophic remodeling of the heart.
Transcription of miR-133a is regulated by 
an IICR-dependent mechanism
Thus far, we have demonstrated that the expression patterns of 
IP3RII and miR-133a are inversely correlated in the cardiomyo-
cyte and that miR-133a restrains pro-hypertrophic IICR. How-
ever, the mechanism whereby miR-133a levels are diminished 
during hypertrophy is unclear. Previously, we and others have 
shown that calcium release via IP3RII regulates pro-hypertrophic 
transcription (Higazi et al., 2009; Nakayama et al., 2010). We 
investigated whether the hypertrophy-associated decrease in 
miR-133a expression is produced by transcriptional inhibition 
and whether the mechanism of miR-133a repression relies on 
IICR. First, we measured expression of miR-133a in NRVMs 
treated with ET-1 to determine whether the response to ET-1 
can be used to study mechanisms of miR-133a suppression. ET-1 
stimulation decreased expression of mature miR-133a (Fig. 5 a) 
and increased levels of IP3RII protein. Overexpression of miR-
133a prevented the ET-1–induced increase in IP3RII (Fig. 5 b), 
which would be anticipated given that miR-133a suppresses 
IP3RII. As calcium released from IP3RII induces hypertrophic 
gene expression, induction of the hypertrophic marker gene 
a target protector (TP) oligonucleotide designed to specifically 
protect the Itpr2 3UTR from miR-133a without affecting other 
miR-133a targets (Choi et al., 2007). TP transfection resulted in 
increased IP3RII abundance compared with control TP (Fig. 4 a), 
whereas expression of another miR-133a target, serum response 
factor (SRF; Liu et al., 2008), was unaltered. The Itpr2 miR-
133a site-specific TP-induced increase in IP3RII expression was 
also observed in experiments in which oligonucleotides target-
ing regions of the Itpr2 3UTR proximal to but not overlapping 
with the miR-133a seed sequence were used instead of the manu-
facturer’s control for transfection. This indicates that the effect 
of the TP was due to inhibition of miR-133a binding to the Itpr2 
3UTR rather than disruption of the Itpr2 3UTR structure 
(Fig. S2). Moreover, in cells transfected with these control TPs, 
SRF expression was unaltered (Fig. S2). Thus, by preventing 
miR-133a binding, the IP3RII TP specifically induces IP3RII 
up-regulation, in the absence of changes in the expression of 
other targets of miR-133a. Using this approach allows the spe-
cific role of miR-133a–mediated regulation of IP3RII expres-
sion in the cardiomyocyte to be interrogated. Therefore, we 
examined whether preventing miR-133a–mediated IP3RII re-
pression by TP transfection is sufficient to induce hypertrophic 
remodeling. Indeed, baseline expression of the hypertrophic 
marker ANF and cell surface area were increased in NRVMs 
transfected with the IP3RII TP (Fig. 4, b and c), confirming that 
the cardiomyocyte hypertrophic response is restricted by the 
inhibitory effect of miR-133a on the IP3RII. Therefore, when 
miR-133a–mediated IP3RII repression is removed, a hypertro-
phic phenotype develops.
miR-133a–mediated regulation of IP3RII 
controls IICR and hypertrophic  
gene expression
We extended our studies regarding the role of miR-133a–mediated 
suppression of IP3RII to the adult rat ventricular myocyte (ARVM), 
giving particular consideration to calcium homeostasis and 
hypertrophic remodeling. At baseline, ARVMs express a low 
level of IP3RII. Under conditions of ryanodine-receptor inhibi-
tion, these receptors produce calcium puffs when stimulated 
with cell-permeant IP3-ester (Tovey et al., 2001; Berridge et al., 
2003; Harzheim et al., 2009). We aimed to repress IP3RII 
expression and consequently IICR by increasing miR-133a 
activity using adenovirus. miR-133a overexpression and the as-
sociated down-regulation of IP3RII were confirmed by qPCR 
(Fig. S3 a) and immunoblotting (Fig. S3 b), respectively. We 
then assessed the effect of increased miR-133a on IP3RII func-
tion in control and miR-133a–overexpressing ARVMs. Fluo-4–
loaded cells were acutely treated with tetracaine to block the 
ryanodine receptor, while the IP3RII was stimulated with IP3-
ester. When miR-133a was overexpressed, IP3-ester elicited sig-
nificantly fewer calcium release events (Fig. 4 d), an effect that 
correlates with reduced IP3RII expression.
As IP3-dependent calcium signals promote hypertrophic 
gene expression (Wu et al., 2006; Higazi et al., 2009; Nakayama 
et al., 2010), we next examined whether miR-133a overexpres-
sion is sufficient to modulate the hypertrophic phenotype both 
in vitro and in vivo. First, we used the spontaneously hypertensive 
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levels were significantly decreased upon ET-1 stimulation 
(Fig. 5 d), showing that reduced transcription rather than 
altered processing mediates the hypertrophy-associated decrease 
in miR-133a.
As pro-hypertrophic transcriptional activity is regulated 
by IICR (Wu et al., 2006; Higazi et al., 2009; Nakayama et al., 
2010), we examined whether this signaling pathway participates 
ANF in response to ET-1 was also prevented by miR-133a over-
expression (Fig. 5 c). These data are consistent with the results 
from the in vivo models of hypertrophy, validating the use of 
ET-1–treated NRVMs to investigate miR-133a repression. Next, 
we tested whether the ET-1–induced reduction in miR-133a has 
a transcriptional mechanism of origin by quantifying expression 
of primary miR-133a (primiR-133a). Interestingly, primiR-133a 
Figure 4. Antagonism of miR-133a–mediated regulation of IP3RII induces the hypertrophic response. (a) Immunoblot for IP3RII and SRF in NRVMs trans-
fected with control or IP3RII-specific target protector (TP) oligos. -Actinin is shown as a loading control. (b) ANF protein expression in NRVMs transfected 
as in a. (c) Cell surface area measurements of NRVMs transfected as in panel a. More than 500 cells were measured per condition. (d) Quantification of 
the fold change in the number of calcium release events elicited by IP3-ester in ARVMs infected with control or miR-133a adenovirus. For each condition, 
at least eight ARVMs were analyzed from three separate experiments. (e) IP3RII protein, mRNA, and nascent RNA expression in WKY and SHR myocytes 
measured by immunoblotting or qPCR. (f) miR-133a expression analyzed by qPCR in WKY/SHR myocytes. (g) Quantification of the hypertrophic phenotype 
by measurement of ANF mRNA expression in GFP/miR-133a-GFP overexpressing WKY and SHR ventricular myocytes. (h) Measurement of LVPWd by 
echocardiography in mice at baseline and after infusion with saline or miR-133a antagomir for 1 mo. (i) Immunoblot for IP3RII in left ventricular samples 
from mice treated with saline/antagomir for 1 mo. (j) Quantification of immunoblots as in i; n = 3. Bar graphs are mean ± SEM from at least three inde-
pendent experiments. *, P < 0.05; ***, P < 0.001.
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IICR and spontaneous mild hypertrophy at 3 mo of age 
(Nakayama et al., 2010). We also investigated the effect of tho-
racic aortic constriction (TAC) on these mice. In control mice 
expressing the tetracycline transactivator (tTA) alone, TAC 
induced a decrease in miR-133a expression (Fig. 6 b) and an 
increase in IP3RII protein expression (Fig. 6 c). At baseline, 
miR-133a expression was lower in IP3RII-TG mice, with no 
further decrease produced upon TAC (Fig. 6 b). These data sup-
port the hypothesis that IICR is a key initiating signal, which 
suppresses miR-133a and induces hypertrophy. Interestingly, 
IP3RII overexpression did not elicit a similar decrease in miR-1 
expression (Fig. S5 a), suggesting that the IICR-mediated 
signal has a specific effect on miR-133a.
Next, we performed the converse experiment, examining 
the effect of inhibition of IICR upon miR-133a and IP3RII 
levels in vivo. To this end, we used mice engineered to induc-
ibly express the IP3-sponge, a fragment of IP3RI spanning its 
ligand-binding domain that binds free IP3 with very high affin-
ity (Uchiyama et al., 2002; Nakayama et al., 2010). These mice 
show blunted hypertrophic responses to systemic infusion with 
the hypertrophic agonists angiotensin II and isoproterenol 
(Nakayama et al., 2010). IP3-sponge mice demonstrated 
elevated baseline miR-133a expression when compared with 
tTA mice (Fig. 6 d) and no significant change in miR-1 expression 
(Fig. S5 b). There was no difference in IP3RII protein expression 
in miR-133a repression. To this end, IICR was inhibited in 
NRVMs by GFP-5P overexpression (Fig. 3 f), and the effect of 
this manipulation on the ET-1–stimulated decrease in miR-133a 
quantitated. GFP-5P prevented both the ET-1–stimulated 
decrease in miR-133a (Fig. 5 e) and increase in IP3RII protein 
expression (Fig. 5 f). These data imply that IICR is required for 
ET-1–induced repression of miR-133a expression and the 
resulting up-regulation of IP3RII. Therefore, by diminishing 
miR-133a expression, IICR enhances expression of its source 
calcium channel. We further substantiated this hypothesis by 
using the Itpr2 3UTR reporter construct (Fig. 2 d) to more di-
rectly measure the repressive action of miR-133a on the Itpr2 
3UTR. Activity of this reporter was increased in NRVMs 
treated with ET-1 (Fig. 5 g), reflecting the ET-1–induced de-
crease in miR-133a. In cells overexpressing GFP-5P, ET-1 did 
not elicit a change in reporter activity, supporting a mechanism 
whereby IICR diminishes miR-133a levels. Together, these 
data suggest an intriguing hypothesis, whereby increases in IP3RII 
expression would create a positive feedback loop to further 
increase IICR, driving miR-133a down-regulation and the hy-
pertrophic response. Having demonstrated in NRVMs that IICR 
controls IP3RII expression through modulation of miR-133a 
levels, we next determined whether this mechanism is con-
served in vivo. Consequently, we examined miR-133a expres-
sion in IP3RII-transgenic mice (Fig. 6 a), which exhibit enhanced 
Figure 5. IICR is required for decreased 
miR-133a expression during hypertrophy.  
(a) miR-133a expression measured by qPCR in 
NRVMs stimulated with 100 nM endothelin-1 
(ET-1) for 24 h. (b) Immunoblot analysis to 
quantify IP3RII protein expression in GFP/miR-
133a-GFP overexpressing NRVMs cultured in 
the presence and absence of ET-1 for 24 h. 
Seven independent immunoblots were quan-
titated. (c) qPCR analysis of the hypertrophic 
response to ET-1 in GFP/miR-133a-GFP over-
expressing NRVMs by quantification of ANF 
mRNA expression. (d) Transcriptional activity 
at the miR-133a locus was measured by qPCR 
quantification of primiR-133a levels in control 
and ET-1-treated NRVMs. e. Measurement of 
miR-133a expression by qPCR in NRVMs in-
fected with GFP/GFP-5P and treated with ET-1 
for 24 h. (f) IP3RII protein expression assessed 
by immunoblotting of NRVM lysates treated 
as in e. At least four blots were quantitated 
per condition. (g) Luciferase assay of NRVMs 
transfected with the Itpr2 3UTR reporter con-
struct, infected with either GFP or GFP-5P and 
treated with ET-1 for 24 h. Data are mean ± 
SEM from at least three independent experi-
ments. *, P < 0.05; **, P < 0.01.
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stimulation. To examine the relationship between miR-133a and 
IICR using an alternative strategy, we analyzed samples from 
IP3RII knockout mice (Fig. 6 g; Futatsugi et al., 2005). miR-
133a expression was significantly increased when the IP3RII 
was absent (Fig. 6 h), whereas miR-1 levels were unaltered 
(Fig. S5 c), mirroring the results observed in IP3-sponge mice. 
Taken together, the in vitro and in vivo data indicate that 
IICR specifically controls expression of miR-133a. Enhanced IICR 
decreases miR-133a expression, whereas inhibition of IICR 
increases miR-133a.
Reduced SRF activity contributes to  
IICR-dependent miR-133a suppression
Although our results demonstrate a role for IICR in regulation 
of miR-133a, a remaining question concerns the mechanism(s) 
between IP3-sponge mice and tTA control mice (Fig. 6 e), which 
is surprising given the alteration in miR-133a expression 
levels. However, analysis of IP3RII RNA levels in the IP3-
sponge mice revealed increased IP3RII mRNA, without a change 
in nascent RNA (Fig. 6 f). These data are suggestive of an adap-
tive mechanism, whereby increased stability of the IP3RII 
mRNA transcript allows IP3RII protein levels to be maintained. 
After TAC, miR-133a expression in the IP3-sponge mice de-
creased to the baseline level observed in the control sham-operated 
tTA mice (Fig. 6 d), without producing an increase in IP3RII 
expression (Fig. 6 e). This is not surprising given that miR-133a 
levels were the same as those observed in control animals. These 
data suggest that miR133a expression must fall below a threshold 
level before IP3RII expression can increase and that in the ab-
sence of IICR, the threshold cannot be breached by hypertrophic 
Figure 6. Manipulation of IICR in vivo alters miR-133a expression. (a) Immunoblot for IP3RII in left ventricular lysates from IP3RII transgenic mice. Tetracy-
cline transactivator protein (tTA) mice are used as controls. (b) miR-133a expression measured by qPCR in tTA/IP3RII transgenic mice subjected to sham 
or TAC procedures. For the tTA sham/TAC and IP3RII-TAC conditions, three mice were analyzed. For the IP3RII-sham condition, two mice were analyzed. 
(c) Representative immunoblot for IP3RII in tTA ventricular lysates ± TAC. (d) qPCR analysis of miR-133a expression in ventricular lysates from tTA controls 
and IP3-sponge (sponge) expressing mice subjected to sham or TAC procedures. For the tTA sham/TAC and IP3-sponge-TAC conditions, three mice were 
analyzed. For the sponge-sham condition, two mice were analyzed. (e) Quantification of immunoblots for IP3RII from sham or TAC operated tTA and sponge 
mice. Two mice were analyzed for the tTA-sham and sponge-sham conditions. Three mice were analyzed for the tTA-TAC and sponge-TAC conditions. 
(f) qPCR measurement of IP3RII mRNA and nascent RNA expression in tTA and sponge mice. Three mice were analyzed for the tTA condition, two mice 
were analyzed for the sponge condition. (g) Example immunoblot of ventricular lysates from wild-type (WT) and IP3RII knockout (KO) mice. (h) miR-133a 
expression measured using qPCR in four WT and four KO mouse samples. Bar graphs show mean ± SEM. *, P < 0.05; **, P < 0.01.
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observations, we demonstrate that HDAC activity is required 
for the ET-1–stimulated decrease in miR-133a. HDAC inhibi-
tion with trichostatin A (TsA) increased basal levels of miR-
133a (Fig. 7 m) and prevented the inhibitory effect of ET-1 on 
miR-133a expression. As has been previously reported (Cao 
et al., 2011), TsA also prevented the ET-1–induced increased in 
ANF expression, confirming the role of HDACs in regulation of 
hypertrophic gene expression (Fig. 7 n).
Discussion
This study delineates an anti-hypertrophic role for miR133a that 
is intrinsic to the ventricular myocyte (Fig. 8). We show that in 
cardiomyocytes, the inhibitory action of miR-133a maintains low 
basal IP3RII expression. Consequently, miR-133a activity holds 
IICR in check and the pro-hypertrophic effect of this pathway is 
restrained. This maintains an appropriate level of myocyte growth 
until the balance between miR-133a and IP3RII is perturbed by 
pathological stimuli that elicit IICR. When IICR is engaged in 
this manner, miR-133a is suppressed via changes in SRF tran-
scriptional activity/targeting. Hence, IP3RII expression increases. 
A deleterious positive feedback loop is generated because en-
hanced IICR promotes sustained repression of miR-133a, pro-
viding a powerful driving force for pathological remodeling. 
Consequently, by inhibiting IP3RII expression and IICR, miR-133a 
would be expected to prevent IICR-dependent pro-hypertrophic 
transcriptional responses.
By specific suppression of miR-133a, calcium arising from 
IP3RII increases expression of its source channel, thereby ampli-
fying the intensity of the pro-hypertrophic calcium signal. This 
creates an inherently unstable system whereby enhanced IICR 
serves to continually repress miR-133a and persistently increase 
IP3RII expression. Interestingly, other pro-hypertrophic positive 
feedback loops have been identified involving miRNAs and the 
signaling pathways that regulate their expression. These include 
miR-1–dependent modulation of insulin-like growth factor-1 sig-
naling (Elia et al., 2009) and miR-199b–mediated regulation of 
the NFAT negative regulatory kinase dual-specificity tyrosine 
phosphorylation–regulated kinase 1a (da Costa Martins et al., 
2010). When taken together, these results indicate that several 
reciprocal regulatory loops may be active within the myocardium 
under pro-hypertrophic conditions. The self-perpetuating nature 
of these loops could serve to produce a sufficiently powerful and 
prolonged stimulus to induce genome-wide remodeling of gene 
expression and hence hypertrophic growth, overcoming mecha-
nisms of negative regulation. The significance of a control loop 
involving miR-133a within this network is increased when col-
lective consideration is given to the postulated targets of this 
miRNA. We have demonstrated regulation of IP3RII, while other 
studies show repression of CnA (Dong et al., 2010) and NFATc4 
(Li et al., 2010a). By targeting the IICR–Cn–NFAT pathway at 
multiple levels, miR-133a is an effective brake on pro-hypertrophic 
transcription. Consequently, when miR-133a levels decline in 
response to IICR, the source of activating calcium (IP3RII), trans-
ducing mechanism (CnA), and effector (NFATc4) of the pathway 
are all up-regulated and pathological gene expression would be 
strongly promoted.
by which IICR signals can repress primiR-133a transcription. It 
is known that the transcriptional regulator SRF targets the miR-
133a locus (Zhao et al., 2005) and it has also been reported to 
inhibit synthesis of the primary miRNA transcript (Zhang et al., 
2011). Thus, we tested whether SRF was involved in IICR- 
mediated regulation of miR-133a expression. Using a SRF- 
sensitive luciferase reporter, we determined that ET-1 stimulates 
SRF transcriptional activity in an IICR-dependent manner in 
NRVMs (Fig. 7 a). Furthermore, ET-1 also up-regulated SRF 
protein levels (Fig. 7, b and c), which is unsurprising given that 
SRF is a known miR-133a target (Liu et al., 2008). To address 
whether SRF has a role in regulation of miR-133a expression, 
we used an adenovirus to overexpress SRF and siRNA to reduce 
SRF expression (Fig. 7, d and e). SRF overexpression increased 
miR-133a (Fig. 7 f), decreased IP3RII protein (Fig. 7, g and h), 
and was without effect on IP3RII mRNA/nascent RNA expres-
sion (Fig. 7 i), indicating a lack of effect of SRF on Itpr2 tran-
scription. Conversely, SRF knockdown increased IP3RII protein 
expression (Fig. 7, g and h). These results are consistent with a 
mechanism whereby SRF positively regulates miR-133a expres-
sion. However, SRF expression and activity are increased under 
hypertrophic stimulation, when miR-133a is down-regulated, 
suggesting a more complex interplay between miR-133a and 
SRF. This was further illustrated through the use of adenovirus 
to overexpress a dominant-negative (DN) form of SRF. DN-
SRF lacks part of the transcription transactivation domain of 
SRF but retains the DNA-binding activity of the full-length pro-
tein (Belaguli et al., 1999). By binding to SRF target sequences 
while being unable to activate transcription, overexpression of 
the mutant has a dominant-negative effect on the activity of 
endogenous SRF. When DN-SRF was overexpressed, baseline 
miR-133a expression decreased (Fig. 7 j). This result supports 
the observation that under nonstimulated conditions, SRF activ-
ity drives miR-133a expression. DN-SRF prevented a further 
decrease in miR-133a expression after ET-1 treatment, imply-
ing that the repressive effect of pro-hypertrophic stimulation is 
mediated through inhibition of SRF transcriptional activity at 
the miR-133a loci.
The ability of SRF to regulate transcription in either an 
activating or repressive manner is determined by which of its 
many interacting proteins it is associated with (Posern and 
Treisman, 2006). We suggest that IICR promotes miR-133a 
suppression by altering the interaction and/or activity of one or 
more of these cofactors with SRF, leading to repression of SRF 
activity. One such protein is the homeodomain-only protein 
(HOP), which negatively regulates SRF-dependent transcrip-
tional responses by recruiting class I HDACs (Kook et al., 
2003). Hence, we next tested whether overexpression of HOP 
by adenoviral infection could mimic the effects of ET-1. miR-
133a levels were diminished in HOP-overexpressing NRVMs, 
with ET-1 failing to elicit a further decrease (Fig. 7 k). In agree-
ment with the reduced level of miR-133a, HOP overexpression 
increased baseline cell surface area (Fig. 7 l), indicative of hy-
pertrophy. These findings support the notion that the inhibitory 
effect of ET-1 on miR-133a expression is mediated via a repres-
sive transcription factor such as HOP, thus promoting develop-
ment of a hypertrophic response. Further strengthening these 
 o
n
 N
ovem
ber 28, 2012
jcb.rupress.org
D
ow
nloaded from
 
Published November 19, 2012
793Reciprocal regulation of IP3RII and miR-133a • Drawnel et al.
Figure 7. IICR affects miR-133a expression through modulation of SRF activity. (a) Luciferase reporter assay of SRF transcriptional activity in GFP/GFP-5P 
overexpressing NRVMs cultured in the presence and absence of 100 nM ET-1 for 24 h. (b) Immunoblot for SRF in control and ET-1–treated NRVM lysates. 
(c) Quantification of immunoblots as in b; n = 6. (d) Immunoblot for SRF in control or SRF-overexpressing NRVMs. (e) Immunoblot for SRF in control or siSRF-
transfected NRVMs. (f) qPCR analysis of miR-133a expression in GFP control, SRF overexpressing, or SRF knockdown NRVMs. (g) Immunoblot to show 
IP3RII expression in GFP-control, SRF-overexpressing, and SRF knockdown NRVMs. (h) Quantification of immunoblots as in g; n = 4. (i) IP3RII nascent RNA 
expression in SRF-overexpressing NRVMs measured using qPCR. (j) qPCR analysis of miR-133a expression in control and DN-SRF–overexpressing NRVMs 
treated with ET-1. (k) miR-133a expression in control or HOP-overexpressing NRVMs cultured in the presence and absence of 100 nM ET-1 for 24 h. (l) Cell 
surface area quantification in control/HOP-overexpressing NRVMs. More than 300 cells taken from 4 separate experiments were measured per condition. 
(m) qPCR analysis of miR-133a expression in NRVMs treated with ET-1 in the presence and absence of 0.4 µM trichostatin A (TsA). (n) qPCR analysis of 
ANF expression in NRVMs treated as in k. Data are mean ± SEM from at least three independent experiments.*, P < 0.05; **, P < 0.01.
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antagomir transfection generated a similar effect on myocyte 
phenotype eliciting both an increase in IP3RII expression and 
hypertrophy. Notably, under these conditions we showed that 
IICR was required for the hypertrophic remodeling that arises as a 
consequence of a reduction in miR-133a activity. These data there-
fore show that as well as suppressing miR-133a abundance, IICR 
is the direct and required downstream mediator of hypertrophy in-
duced by reduced miR-133a and further emphasizes the impor-
tance of miR-133a–mediated inhibition of IP3RII for the restriction 
of pathological cellular growth. However, other studies have indi-
cated that miR-133a maintains cardiac function via anti-apoptotic 
and anti-fibrotic effects within the adult myocardium (Matkovich 
et al., 2010). Some of the differences in the published data can be 
accounted for by variation in experimental model, the developmen-
tal stage from which miR-133a is expressed, the time-point 
at which observations are taken, and the extent to which adaptive 
mechanisms may be engaged in transgenic animals. Nevertheless, 
given the multitude of targets of any one miRNA and the complex-
ity of regulation of myocyte gene expression networks, it is con-
ceivable that more than one function exists for miR-133a in the 
maintenance of the healthy adult heart. Furthermore, the gross ef-
fect of a lack of miR-133a activity may change depending on 
the extent of disease progression, with different functions taking 
center stage over time. We believe that our data, by defining both 
a cause and consequence of dysregulated miR-133a centered on 
the IP3RII, provide a new insight into how remodeling of calcium 
signaling and transcription promotes arrhythmias, left-ventricular 
hypertrophy, and eventually, heart failure.
Materials and methods
Animal procedures
All experiments involving animals were performed in accordance with 
local ethical and welfare guidelines. Specifically, for experiments in the 
UK, in accordance with the guidelines from the code of practice for hu-
mane killing under Schedule 1 of the Animals (Scientific Procedures) Act 
1986 (UK); for experiments in Norway, The Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH 
publication no. 85–23, revised 1996); for experiments in the USA, The 
Institutional Animal Care and Use Committee (Cincinnati, OH); and for ex-
periments in Japan, the Japanese Physiological Society.
Antibodies and other reagents
Antiserum against the IP3RII C-terminal region (NH2-CLGSNTPHVHHMPPH-OH) 
was raised in rat (Harzheim et al., 2009) and used for immunoblotting (IB) at 
The IICR-dependent transcriptional mechanism of origin 
for disease-associated repression of miR-133a is a significant 
finding. The murine genome encodes two copies of miR-133a: 
miR-133a-1 and miR-133a-2. These are located in the mouse in 
the vicinity of and cotranscribed with the sequences for miR1-2 
and miR-1-1, respectively (Liu et al., 2007). Muscle-specific 
expression of the miR-133a, miR-1 bicistron is regulated by 
SRF and MEF2 (Zhao et al., 2005; Liu et al., 2007). Therefore, 
it is intriguing that miR-133a and miR-1 are repressed during 
hypertrophy, when global SRF activity is enhanced. However, 
different context-dependent modes of operation of SRF have 
been reported in other cellular systems, allowing a variable pat-
tern of gene expression to be elicited without a change in bulk 
SRF activity (Wang et al., 2004). This is achieved through the 
association of SRF with diverse function-specific cofactors 
(Niu et al., 2007) including HOP, Nkx2.5, GATA4, Elk1, and 
myocardin. Regulation of these cofactors by intracellular sig-
naling pathways allows positive or negative regulation of SRF 
in response to cellular stimulation. As calcium regulates multi-
ple signal transducers including CaMKII, Cn-NFAT, and pro-
tein kinase C, there are a number of plausible mechanisms 
whereby the activity of SRF could be altered in response to 
IICR, preventing transcriptional activity at the miR-133a loci. 
We show that hypertrophy-associated decreases in miR-133a 
require HDAC activity and that overexpression of a dominant-
negative SRF mutant or the negative transcriptional regulator 
HOP mimics the effect of ET-1 stimulation. This suggests that 
repression of SRF activity at the miR-133a loci may be a driv-
ing mechanism for the hypertrophy-associated decrease in miR-
133a. Future work will aim to establish how IICR mediates 
decreased miR-133a expression via SRF, without similarly 
repressing expression of miR-1. The presence of additional tran-
scription factor response elements between the miR-1 and miR-
133a genes provides the potential for mechanisms of differential 
regulation (Thum et al., 2008).
Our data are consistent with previously published observa-
tions, which demonstrated that manipulation of miR-133a activity 
in vivo is sufficient to mediate pathological cardiac growth. In par-
ticular, infusion of miR-133a antagomir is sufficient to induce hy-
pertrophic remodeling in adult mice (Carè et al., 2007). We have 
demonstrated that under these conditions, IP3RII expression is 
increased, thus amplifying pro-hypertrophic IICR. miR-133a 
Figure 8. IICR engages a pro-hypertrophic positive feed-
back loop. Schematic diagram to represent how loss of 
miR-133a–mediated IP3RII repression generates a positive 
feedback loop to drive the hypertrophic response.
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Adult rat thoracic aortic constriction and echocardiography
170-g male Wistar rats were anesthetized by a mixture of 67% N2O, 
27% O2, and 4% isoflurane, and subsequently intubated and ventilated with 
a mixture of 67% N2O, 28% O2, and 2% isoflurane. The ascending aorta was 
dissected through a right-sided thoracotomy, and a silk suture (3–0) was tight-
ened around the ascending aorta and a steel wire (0.85 mm) proximal to the 
brachiocephalic trunk as described previously (Brattelid et al., 2007). Immedi-
ately after the ligation, the steel wire was removed. The chest was closed and 
the rats extubated. Sham-operated animals served as controls and underwent 
the same surgical procedure, except tightening the silk suture around the as-
cending aorta. Buprenorphine was given as postoperative analgesia.
6 wks after aortic banding, rats were anesthetized by a mixture of 
66% N2O, 27% O2, and 4% isoflurane, and subsequently mask ventilated 
with a mixture of 67% N2O, 28% O2, and 2% isoflurane. Vevo 2100 (Visual-
Sonics) with a 24-MHz Microscan linear phased array transducer was used 
to obtain echocardiographic examinations. Ventricular dimensions and Dop-
pler signals were recorded in the parasternal long axis view. After echocar-
diography, rats were intubated and ventilated through endotracheal 
intubation. The chest was opened, followed by excision of the heart. The four 
heart chambers were rapidly dissected, weighed, and frozen in liquid nitro-
gen. Left ventricular myocardium was used for further molecular analysis.
Mouse models
Protocols for generation of IP3RII and IP3-sponge transgenic mice and TAC of 
modified mice have been described previously (Nakayama et al., 2006, 
2010). Cardiac-specific expression of mouse IP3RII or flag-tagged IP3-sponge 
protein was generated by placing the respective cDNAs under the control of 
the inducible -myosin heavy chain promoter (Sanbe et al., 2003). Transgenic 
mice overexpressing these proteins were crossed with driver tetracycline trans-
activator transgenic mice. IP3RII knockout mice are disrupted within the first 
coding exon of the Itpr2 gene (Futatsugi et al., 2005). Single-transgenic 
miR133a-1neo/+ or miR133a-2neo/+ knockout mice were generated by replac-
ing 68 bp of the premiR133a-1 stem-loop or 108 bp of the premiR133a-2 
stem-loop with a neomycin resistance cassette flanked by 2 FRT sites (Liu et al., 
2008). Double heterozygote mice were generated by crossing miR133a-1neo/+ 
with miR133a-2neo/+ mice and then intercrossed to obtain double knockout 
mice lacking both miR133a-1 and miR133a-2.
Methods for infusion of mice with saline or the antagomir oligo via 
osmotic mini-pump are described in Carè et al. (2007). In brief, antagomirs 
were dissolved in saline solution at doses of 80 mg/kg body weight and 
loaded in Alzet osmotic minipumps (model 1003D; Alza). To prime the 
pumps for continuous delivery of the antagomir, loaded minipumps were 
placed in a flask with saline solution and incubated for 4 h at 37°C. Acti-
vated minipumps were then implanted subcutaneously.
Molecular biology and preparation of adenovirus
To construct the Itpr2 3UTR luciferase reporter, the Itpr2 3UTR was PCR am-
plified from rat liver genomic DNA and cloned into psiChk2 (Promega). Due 
to the presence of an internal XhoI site within the Itpr2 3UTR, PCR amplifica-
tion and subcloning was performed in two stages. First, the 3UTR was PCR 
amplified, digested with XhoI and NotI, and inserted into psiChk2. Forward 
primer sequence: 5-CACCGCTCGAGCACCATGGGGGCACGCCGT-
GAC-3, reverse primer sequence: 5-CAGTGGCGGCCGCCTAATTACA-
AACAATTATTTTAAT-3. This inserted the 3 section of the 3UTR into psiChk2. 
Next, the 5 end of the 3UTR was PCR amplified, digested with XhoI, and 
inserted into the XhoI site of psiChk2 to recreate the full-length Itpr2 3UTR. 
Forward primer sequence: 5-CACCGCTCGAGCACCATGGGGGCAC-
GCCGTGAC-3, reverse primer sequence: 5-GTTGGCTGTTACCCTC-
GAGTTT-3. The resulting product was sequenced to ensure fidelity with the 
genomic sequence. To mutate the miR-133a binding site within the Itpr2 
3UTR, QuikChange site-directed mutagenesis (Stratagene) was performed 
at eight positions, according to the manufacturer’s instructions.
The miR-133a precursor transcript was PCR amplified from rat liver 
genomic DNA and cloned into psi-RNA-h7SK-GFP (Invivogen) using the 
Acc651 and HindIII sites. Forward primer sequence: 5-CCTAGGTACCA-
GACTCTACACTAGTGTGGGACCCTC-3, reverse primer sequence: 5-CAT-
AAAGCTTTCAAGAAACATC-3. To allow generation of adenovirus, 
miR-133a was PCR amplified from psi-RNA-h7SK-GFP miR-133a and in-
serted into the MluI and HindIII sites of pRNAT H1.2 Adeno (Genscript). 
Forward primer sequence: 5-GGTACCACGCGTACACTAGTGTGGGA-
CCCTC-3, reverse primer sequence: 5-CATAAAGCTTTCAAGAAACATC-3. 
A nonfluorescent adenoviral shuttle vector (pShuttle H1 miR-133a) was cre-
ated by subcloning the H1 promoter and miR-133a from pRNAT H1.2 
miR-133a into pShuttle using the BglII and HindIII sites. C-myc–tagged 
HOP sequence was excised from pcDNA3.1 HOP (a gift from J.A. Epstein, 
1:400 dilution and immunofluorescence (IF) at 1:50 dilution. Other anti-
bodies were: RyR2 (IF 1:50; a gift from V. Sorrentino, University of 
Siena, Siena, Italy), calsequestrin (IB 1:15,000; PA1-913, Affinity Bio-
reagents), calnexin (IB 1:20,000; C4731, Sigma-Aldrich), -actinin (IF 1:500; 
A7732; Sigma-Aldrich), and ANF (IF 1:500; T-4014, Bachem). Endothe-
lin-1 was purchased from EMD Millipore. siRNA (Stealth) were from Invit-
rogen, miR-133a antagomirs were from GenePharma Ltd. Negative control 
target protector and custom target protectors C1, C2, and IP3RII were 
designed by and purchased from QIAGEN. Adenovirus to express SRF 
was from T. Lee (Suny at Buffalo, Buffalo, NY). Unless stated otherwise, all 
other chemicals were purchased from Sigma-Aldrich.
HEK293 cell culture
HEK293 cells (Microbix) were cultured using standard tissue culture meth-
ods and maintained in DMEM medium containing 10% FBS and 1% 
penicillin/streptomycin/l-glutamine.
Preparation of neonatal rat ventricular myocytes
Cell isolation was essentially performed as described elsewhere (Higazi 
et al., 2009). In summary, Wistar rats (P3, Charles River Laboratories) 
were sacrificed by cervical dislocation and ventricles of beating hearts 
excised and placed in ice-cold neonatal myocyte buffer (20 mM Hepes, 
100 mM NaCl, 5.4 mM KCl, 0.8 mM MgSO4. 0.1% d-glucose, and 0.8 mM 
NaH2PO4.H2O, pH 7.35). After washing to remove excess blood, hearts 
were minced into 2-mm3 pieces using scissors and placed in 37°C diges-
tion buffer (neonatal myocyte buffer containing 126 U/ml collagenase 
type II [Worthington], 0.2 mg/ml pancreatin, and 0.015 mg/ml DNase I 
[Roche]). Tissue was digested at 30°C with shaking at 190 rpm. 6 × 20-min 
digests were performed, and at the end of each incubation the tissue 
was triturated and the supernatant placed in myocyte plating medium 
(DMEM/M199 4:1 [Invitrogen], 10% donor horse serum [Invitrogen], 5% 
fetal calf serum [Invitrogen], 1 mM sodium pyruvate [PAA], 1× MEM non-
essential amino acids [Invitrogen], 1× antibiotic-antimycotic [Invitrogen], 
and 3 µM cytosine -d-arabinofuranoside). After every second digest, plat-
ing medium plus digested supernatant was passed through a 100-µm cell 
strainer and isolated cells collected by centrifugation (5 min, 390 g, room 
temperature). At the end of the digests, resuspended cells were preplated 
in a T175 flask and incubated for 45 min at 37°C to allow contaminating 
fibroblasts to adhere. Subsequently, myocytes were recovered by centrifu-
gation (5 min, 390 g, room temperature). Cells were plated onto tissue 
culture vessels coated with 1% gelatin. Cultures were >95% pure. 48 h after 
plating, myocytes were washed into serum-free medium (DMEM/M199 
4:1, 1 mM sodium pyruvate, 5.5 µg/ml transferrin, 5 ng/ml sodium selenite, 
1× antibiotic-antimycotic, and 3 µM cytosine -d-arabinofuranoside). 
Adenoviral infections were performed by incubation with a volume of virus-
containing serum-free medium sufficient to cover the cells for 4 h. Agonist 
treatments diluted in serum-free medium were applied 24 h after infection 
with adenovirus.
Isolation and culture of ARVMs
Male SHR and WKY rats (Harlan) were anaesthetized by CO2 inhalation 
and killed by cervical dislocation. After the thorax was opened, the heart 
was cannulated via the aorta and mounted on a modified Langendorff 
apparatus. All buffers were warmed to 37°C and oxygenated before use. 
Hepes buffer (10 mM Hepes, 135 mM NaCl, 5.4 mM KCl, 10 mM d-glucose, 
2 mM MgCl2, and 1 mM CaCl2, pH 7.35) was perfused in a retrograde 
manner for 4 min after which a low calcium buffer (10 mM Hepes, 120 mM 
NaCl, 5.4 mM KCl, 20 mM taurine, 20 mM d-glucose, 5 mM MgSO4, 
5 mM sodium pyruvate, 5.5 mM NTA, and 80 µM CaCl2, pH 6.98) 
was perfused for 3.5 min. Enzyme buffer (10 mM Hepes, 120 mM NaCl, 
5.4 mM KCl, 20 mM taurine, 20 mM d-glucose, 5 mM MgSO4, 5 mM so-
dium pyruvate, 35 µM CaCl2, and 319 U/ml collagenase type II [Worthing-
ton], pH 7.4) was circulated for 9.5 min. The heart was then removed from 
the apparatus and cut into 3-mm3 chunks. 30 ml enzyme solution was 
added and an incubation performed for 4.5 min with shaking at 300 oscil-
lations/min. Enzyme solution was replaced and a second 4.5-min incubation 
performed. The supernatant was then replaced with enzyme solution lack-
ing collagenase and the tissue triturated to release cells. Supernatant con-
taining cells was transferred to a fresh tube and the cells allowed to sediment 
under gravity. The resulting pellet was resuspended in adult myocyte 
medium (M199, 1% penicillin/streptomycin/l-glutamine, and 0.2% BSA) 
and the cells plated onto laminin-coated (25 µg/ml; Invitrogen) dishes. 
Cells were allowed to adhere for 1 h before replacement of medium. 
Adenoviral infections were performed overnight in a minimal volume of 
virus-containing medium.
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room temperature with Hoescht (1 µg/ml in PBS; Invitrogen). Images were 
captured at room temperature using the Pathway 855 high-content imaging 
system (BD) and AttoVision software (BD). The microscope was equipped 
with a 40× (0.75 NA) UPlan FLN air objective (Olympus) and an Orca 
ER camera (Hamamatsu Photonics). For surface area measurements, im-
ages were analyzed by drawing around the edge of the cells in ImageJ 
(National Institutes of Health). At least 400 cells from 3 independent exper-
iments were analyzed. These images were also used to quantify ANF pro-
tein expression by counting the number of NRVMs exhibiting a perinuclear 
ring of ANF.
For analysis of IP3RII and RyR2 expression in isolated ventricular 
myocytes from sham and AB rats, myocytes were permeabilized for 15 min 
in 0.2% Triton X-100/PBS. Nonspecific antibody binding was blocked by 
incubation in blocking buffer (5% chemiblocker [EMD Millipore] in 0.1% 
Triton X-100/PBS) for 1 h at 4°C. Primary antibodies were diluted in blocking 
buffer and incubations performed overnight at 4°C. Alexa Fluor 488– and 
647–coupled secondary antibodies were diluted 1:500 in blocking buffer 
and incubated for 1 h at 4°C. Samples were mounted onto slides using 
Vectashield with DAPI (Vector Laboratories). Confocal imaging was per-
formed at room temperature using a microscope (model A1R; Nikon) and 
a violet-corrected 60× oil immersion objective (1.4 NA). Cells were im-
aged at a zoom of 1.79, which allowed for a whole cell to be imaged in 
the image field. Dimensions were in the order of 0.11 µm/pixel and z-sections 
were taken at 0.15-µm intervals through a 5-µm volume around the mid- 
nuclear plain. Stacks were deconvolved using AutoQuant software (setting 
high noise, with 10 iterations). For 2D Fourier analysis (FFT), the mid- 
nuclear section of these stacks was rotated so that the z-line striations were 
located horizontally in the field (using ImageJ) and an area of 200 × 200 
pixels was cropped. Care was taken for the cropped image to contain both 
the perinuclear and the junctional regions of the myocyte. These images 
were then submitted to 2D Fourier analysis (ImageJ).
Confocal calcium imaging
WKY myocytes cultured on laminin-coated 16-mm coverslips were infected 
overnight with adenovirus to overexpress miR-133a or with empty vector 
control virus (both without fluorescent protein expression). The next morning, 
culture medium was removed and cells were loaded with 8 µM fluo-4 (Invit-
rogen) in Hepes buffer for 30 min at room temperature. After this incubation 
and one wash in Hepes buffer, cells were incubated in Hepes buffer for a 
further 30 min to de-esterify the dye. Coverslips were then placed in a pac-
ing chamber on the stage of a confocal imaging system (A1R; Nikon) and 
electrically paced at 0.33 Hz, 30 V at room temperature throughout the ex-
periment. Only rod-shaped cells showing regular calcium transients in re-
sponse to pacing were selected for further analysis. Movies were captured 
in NIS elements software at 120 frames/s with averaging every 2 frames, 
section thickness = 1.52 µm, using a 60× (1.40 NA) Apo violet-corrected oil 
objective (Nikon) and 488-nm laser to excite fluo-4 fluorescence. Imaging 
was performed for 20 s every 30 s with the addition of 1 mM tetracaine in 
Hepes buffer and 1 mM tetracaine + 10 µM IP3 ester (a gift from S. Conway, 
University of Oxford, Oxford, UK) at the start of the second and third movies, 
respectively. A total of six movies was captured per cell. ImageJ was used to 
background subtract the data. Calcium release events were detected using 
SparkSpotter, an ImageJ plugin developed by Babraham Bioinformatics, 
which counted events with at least 100 intensity units difference above the 
mean value that lasted at least 4 frames.
Statistical analysis
Results are presented as mean ± SEM. Statistical analyses were performed 
in GraphPad Prism using the one-sample t test for two groups and one-way 
Anova followed by Tukey analysis for two or more groups. P values <0.05 
were considered significant.
Online supplemental material
Fig. S1 (a and b) shows 2D Fourier analysis of IP3RII and RyR2 expression 
in ventricular myocytes from sham and AB rats. Fig. S1 c shows qPCR 
quantification of miR-133a expression in cardiomyocytes and noncardio-
myocytes. Fig. S2 shows IP3RII expression in NRVMs transfected with con-
trol TPs or specific IP3RII TP. Fig. S3 a shows qPCR quantification of 
miR-133a expression levels in ARVMs expressing GFP/GFP-miR-133a. 
Fig. S3 b shows IP3RII protein expression in ARVMs expressing GFP/GFP-
miR-133a. Fig. S4 a is an immunoblot showing IP3RII expression in control 
mice and mice infused with scrambled miR-133a antagomir. Fig. S4 b is 
quantification of blots as in Fig. S4 a. Fig. S5 a is qPCR quantification of 
miR-1 expression in control and IP3RII-transgenic mice. Fig. S5 b shows 
miR-1 expression in control mice and mice overexpressing the IP3-sponge 
University of Pennsylvania, Philadelphia, PA) using PmeI and inserted into 
EcoRV-digested pShuttle-CMV. Recombinant adenoviral constructs were 
produced from pRNAT H1.2 miR-133a GFP, pShuttle H1 miR-133a, and 
pShuttle CMV HOP using the AdEasy method (Luo et al., 2007). PacI-digested 
recombinant plasmids were transfected into HEK293 cells and crude ade-
novirus harvested after 10–14 d. This crude viral preparation was used for 
large-scale amplification of virus in HEK293 cells, which was purified using 
the Vivapure Adenopack 100 (Sartorius).
Gene expression analysis
Total RNA was isolated from cardiac myocytes and tissue samples using 
the miRVana-miRNA isolation kit (Ambion) and cDNA was synthesized 
from 500 ng total RNA using the NCode Vilo miRNA cDNA synthesis kit 
(Invitrogen). qPCR was performed using SYBR-GreenER (Invitrogen) and 
primers specific for the sequence of interest. Reactions were performed 
using a Real-Time PCR Cycler (model CFX96; Bio-Rad Laboratories). For the 
analysis of mRNA expression, primers amplified targets spanning exon–
exon boundaries. To analyze nascent RNA, expression primers amplified 
targets within the intron, allowing unspliced IP3RII RNA to be quantified. 
GAPDH, 2-microglobulin, and troponin T were used as internal normaliza-
tion controls. Analysis was performed using the comparative Ct method 
(Vandesompele et al., 2002), whereby the geometric mean of the expres-
sion levels of three independent normalization controls is calculated and 
used as a normalization factor to compare the expression level of the gene 
of interest between samples from different experimental conditions.
Protein expression analysis
Tissue samples were placed in lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM 
DTT, 1 mM EGTA, and protease and phosphatase inhibitor cocktails 
[Sigma-Aldrich]) and homogenized in a lysing matrix D tube (MP Bio) for 
30 s at 40 m/s in a FastPrep machine (MPBio). Debris was pelleted by 
centrifugation for 1 min at 3,500 g and the remaining supernatant incu-
bated on ice for 30 min. Cultured cells were harvested by scraping in PBS, 
recovered by centrifugation, resuspended in lysis buffer, and incubated on 
ice for 30 min. The membrane fraction was recovered from all sample 
types by centrifuging the lysate for 15 min at 100,000 g (4°C), and the re-
sulting pellet solubilized in lysis buffer containing 140 mM NaCl and 1% 
Triton X-100. Protein concentration was determined using the BCA assay 
(Thermo Fisher Scientific) and equivalent amounts of protein were resolved 
on 7% SDS polyacrylamide gels. Proteins were transferred to PVDF mem-
branes and analyzed by immunoblotting with appropriate primary anti-
bodies and HRP-conjugated secondary antibodies. Immunoreactive bands 
were detected by enhanced chemiluminescence (Thermo Fisher Scientific).
Transfections
HEK293 cells cultured in 48-well dishes were transfected with the Itpr2 
3UTR reporter/mutant 3UTR reporter and psi-RNA-h7SK-GFP miR-133a 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s in-
structions. Lipofectamine 2000 was also used for transfection of NRVMs 
with the Itpr2 3UTR reporter, antagomir oligos, and siRNA. For target pro-
tector (TP; QIAGEN) transfection of NRVMs, Dharmafect I and Accell me-
dium (Dharmacon) were used according to the manufacturer’s protocol. 
TPs were: manufacturer’s negative control without homology to any known 
mammalian gene, Itpr2 miR-133a-site specific TP, TP C1, which binds 89 
base pairs downstream of the miR-133a site, and TP C2, which binds 306 
base pairs downstream of the miR-133a site. C1 and C2 were designed to 
bind to sites proximal to, but not overlapping with the miR-133a site and 
within regions of the Itpr2 3-UTR without binding sites for known hypertro-
phy-associated miRNAs.
Luciferase reporter assay
NRVMs or HEK293 cultured in 48-well dishes were lysed using 1× passive 
lysis buffer (Promega). Luciferase reporter assays were performed using 10 µl 
lysate and the dual reporter luciferase assay kit (Promega), according to 
the manufacturer’s protocol.
Immunofluorescence analysis
For analysis of cell surface area, NRVMs were cultured in Falcon black 96-
well imaging plates (BD) coated with 1% gelatin. At the end of the experi-
ment, cells were washed in PBS and fixed by incubation in PBS containing 
2% paraformaldehyde/0.05% glutaraldehyde for 15 min at room temper-
ature. Immunofluorescent staining of cells for -actinin and ANF was per-
formed as in Higazi et al. (2009). Alexa Fluor 488– and 568–coupled 
secondary antibodies (Invitrogen) were used at 1:500 dilution. At the end 
of the staining protocol, nuclei were stained by incubation for 20 min at 
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Figure S1.  IP3RII protein and miR-133a expression is altered in hypertrophic ventricular myocytes. (a and b) 2D Fourier analysis of deconvolved confocal 
images of isolated ventricular cardiomyocytes from sham or AB rats immunostained for (a) RyR2 and (b) IP3RII. Note the increase in the high frequency popu-
lation of pixels positive for IP3RII in AB samples and the lack of a corresponding alteration in RyR2 pixel frequency. For the sham condition, 16 cells from 
2 independent preparations were analyzed. For the AB condition, 26 cells from 2 independent preparations were analyzed. (c) qPCR quantification of 
miR-133a expression in sham (n = 5) and AB (n = 4) cardiomyocyte and sham (n = 5) and AB (n = 5) noncardiomyocyte cell populations. Data are mean 
± SEM. *, P < 0.05.
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Figure S2.  IP3RII up-regulation is a specific effect of the IP3RII target protector. Immunoblot for IP3RII in lysates from NRVMs transfected with control target 
protector oligos C1 and C2 or the miR-133a–specific oligo (IP3RII). C1 and C2 are designed to target regions of the Itpr2 3UTR downstream of the miR-
133a binding site. -Actinin is shown as a loading control.
Figure S3.  miR-133a-GFP overexpression down-regulates IP3RII in ARVMs. (a) qPCR analysis of miR-133a expression in GFP/miR-133a-GFP overexpress-
ing ARVMs. Data are mean ± SEM from five independent experiments. (b) Quantification of immunoblots for the IP3RII in GFP/miR-133a-GFP overexpress-
ing ARVMs. Data are mean ± SEM from seven independent experiments. *, P < 0.05.
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Figure S4.  IP3RII expression in unaffected by infusion of scrambled miR-133a antagomir. (a) Immunoblot for IP3RII in ventricular lysates from control mice 
or mice infused with a scrambled miR-133a oligonucleotide for 1 mo. CLNX and CSQ are shown as loading controls. (b) Quantification of immunoblots 
as in panel a. Data are from six control and three scrambled oligonucleotide-treated mice. Bar graphs represent mean ± SEM.
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Figure S5.  miR-1 expression is not regulated by IICR. (a) miR-1 expression measured by qPCR in IP3RII transgenic mice subjected to sham or TAC proce-
dures. Three mice were analyzed for the tTA sham/TAC and IP3RII TAC data. Two mice were analyzed for the IP3RII sham condition. (b) qPCR analysis of 
miR-1 expression in ventricular lysates from tTA controls and IP3-sponge (sponge) expressing mice subjected to sham or TAC procedures. Three mice were 
analyzed for the tTA sham/TAC and sponge-TAC data. Two mice were analyzed for the sponge-sham condition. (c) miR-1 expression measured using qPCR 
in WT and KO mouse samples. Four WT and four KO mice were analyzed. Data are mean ± SEM.
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